VINORELBINA TEVA 10mg / ml perfusive solution concentrate medication leaflet

L01CA04 vinorelbine • Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Vinca alkaloids and analogues

Vinorelbine is a chemotherapy medication used for the treatment of various types of cancer, including non-small cell lung cancer and advanced breast cancer. It belongs to the vinca alkaloid class and works by inhibiting tubulin polymerization, which leads to the arrest of cell division and ultimately tumor cell death.

Vinorelbine is administered intravenously or orally, depending on the type and stage of cancer, and the dosage is adjusted based on body weight and patient response. Treatment is usually given in cycles to allow the body to recover between doses.

Common side effects include nausea, vomiting, fatigue, alopecia, and myelosuppression (reduction in blood cell counts). In rare cases, severe adverse reactions such as peripheral neuropathy or liver function impairment may occur.

Patients receiving vinorelbine should be regularly monitored for hematologic function and signs of toxicity. The medication is an important option in cancer treatment, helping to reduce tumor size and prolong patient survival.

General data about VINORELBINA TEVA 10mg / ml

Substance: vinorelbine

Date of last drug list: 01-06-2025

Commercial code: W64798002

Concentration: 10mg / ml

Pharmaceutical form: perfusive solution concentrate

Packing volume: 5 ml

Product type: generic

Price: 389.06 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: SINDAN PHARMA S.R.L. - ROMANIA

Holder: TEVA B.V. - OLANDA

Number: 13124/2020/01

Shelf life: 3 years

Concentrations available for vinorelbine

10mg/ml, 20mg, 30mg, 50mg/5ml, 80mg

Other substances similar to vinorelbine

Compensation lists for VINORELBINA TEVA 10mg / ml TEVA

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

389.06 RON

322.15 RON

66.91 RON